Overall verdict
Sell
1.4/10
1-year performance
+2.72%
Score breakdown
Up 2.7% over 1 year, 10% of the 52-week range.
Strongest: Financial strength 7.5/10. Weakest: Profitability 0.0/10.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad ; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic.
It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Sector
Health Care
Industry
Biotechnology
Primary listing
Twse
Taiwan
CEO
Ya-Chun Wang
Founded
1998
Employees
—
Revenue / employee
—
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
290.00 TWD
52-week low
135.00 TWD
1-year performance
2.72%
Rising
Year-to-date performance
2.72%
Rising
Drawdown
-47.93%
Major drawdown
Position in the 52-week range
10% of range
Gross margin 42.6%, the company loses 4.5% of its revenue, ROIC -2.1%, ROE -2.1%.
Net margin
-4.49%
Negative
Sector -14.62%|S&P 13.15%
Gross margin
42.59%
Low
Return on equity (ROE)
-2.09%
Negative
Sector -15.94%|S&P 16.61%
Return on invested capital (ROIC)
-2.12%
Negative
Free cash flow margin (FCF)
-0.29%
Negative
Margin stability
1.7 pts
Very steady
Revenue to net income
Growth
0.3/10Revenue up 10.0% over 1 year, -1.4% a year over 5, EPS -8.6% a year over 5.
Revenue (trailing 12 months)
690M TWD
Revenue growth (1y)
9.95%
Solid
Revenue growth (3y)
-14.57%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
-8.55%
Declining
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 30.7x|S&P 24.1x
Forward P/E
167.8x
Very expensive
EV / EBITDA
—
N/A (loss)
Sector 22.8x|S&P 15.2x
PEG
—
Sector 1.09|S&P 0.90
Market cap
10.3Md TWD
Financial strength
7.5/10Cash covers 4809.6% of the debt, net debt/EBITDA -11.9x.
Net debt / EBITDA
-11.9x
Net cash
Gearing (net debt / equity)
-59.96%
Net cash
Cash
1.2Md TWD
Cash / market cap
11.46%
Solid
Cash / total debt
4809.60%
Net cash
Interest coverage
-57.5x
Stretched
Net debt
-1.2Md TWD
Equity
1.9Md TWD
Closed daily candles, 2 years
Last close on October 21, 2026: 156.00 TWD
- MM20148.55
- MM50150.54
- MM200174.59
- RSI 1458.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.73%
200-day average slope, 3 months
+0.42%
50-day average slope, 1 month
-16.31%
Bullish RSI divergence
No
20-day volatility
2.65 % per day
Volatility change
-30.59%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 0.90 | 0.90 | 700 | 76 | 53 |
| 2027 | 1.77 | 1.77 | 842 | 140 | 105 |
Amounts in millions of TWD, EPS in TWD per share. In brackets, the number of analysts. Consensus as of April 28, 2026.
Same sub-industry: 411 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VRTX | 6.2 | 5.8 | 133Md USD | 30.5x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 25.6 % | ||
| 2 | ABBV | 6.0 | 5.1 | 503Md USD | 80.5x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.6 % | 22.7 % | ||
| 3 | AMGN | 6.0 | 5.9 | 237Md USD | 27.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.3 % | 44.9 % | ||
| 4 | REGN | 5.7 | 5.6 | 82.9Md USD | 19.9x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.5 % | 40.2 % | ||
| 5 | CSL | 4.7 | 3.9 | 66.1Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | -11.0 % | ||
| 6 | GILD | 4.4 | 3.0 | 190Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.8 % | 24.6 % | ||
| 7 | NTRA | 4.3 | 3.0 | 59.6Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 119.9 % | ||
| 8 | MRNA | 2.8 | 1.3 | 98.1Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.3 % | 802.1 % | ||
| 9 | 4169 | 1.4 | 1.4 | 317M USD | Not meaningful (loss) | -4.5 % | 10.0 % | -2.1 % | -11.9x | -0.0 % | 2.7 % |
